CDN1163|cas:892711-75-0|西域试剂

CDN1163,99.77%

产品编号：Bellancom-101455| CAS NO：892711-75-0| 分子式：C₂₀H₂₀N₂O₂| 分子量：320.39

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101455	￥770.00	杭州北京（现货）
Bellancom-101455	￥1250.00	杭州北京（现货）
Bellancom-101455	￥4300.00	杭州北京（现货）
Bellancom-101455	￥7700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CDN1163

产品介绍

CDN1163 是一种肌膜/内质网 Ca²⁺-ATPase (SERCA) 的变构激活剂，可改善 Ca²⁺ 稳态。CDN1163 可减轻糖尿病和代谢紊乱。

生物活性

CDN1163 is an allosteric sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) activator that improves Ca²⁺ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.

体外研究

CDN1163 (10 μM; 24 hours; rat cardiac myocyte cells) treatment reduces high glucose-induced resistin and nuclear NFATc expression and increases the phosphorylation of AMPKα in a time-dependent manner.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Rat cardiac myocyte cells (H9c2)
Concentration:	10 μM
Incubation Time:	24 hours
Result:	High glucose-induced resistin and nuclear NFATc expression are significantly reduced. The phosphorylation of AMPKα is increased in a time-dependent manner.

体内研究
(In Vivo)

CDN1163 (50 mg/kg; intraperitoneal injection; for 5 days; male ob/ob mice and lean ob/+ mice) increases SERCA2 Ca²⁺-ATPase activity, decreases endoplasmic reticulum (ER) stress-induced cell death in vitro and improves liver Ca²⁺ transport activity. CDN1163 reduces blood glucose levels and improves metabolic parameters and gluconeogenic gene expression, reverses hepatic steatosis, inhibits ER stress and ER stress-induced apoptosis, and improves mitochondrial efficiency in ob/ob mice in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 8-10-week old ob/ob mice and lean ob/+ mice
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; for 5 days
Result:	Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 8-10-week old ob/ob mice and lean ob/+ mice
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; for 5 days
Result:	Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 8-10-week old ob/ob mice and lean ob/+ mice
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection; for 5 days
Result:	Markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis but did not alter glucose levels or body weight. Increased expression of uncoupling protein 1 (UCP1) and UCP3 in brown adipose tissue and reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis, possibly through SERCA2-mediated activation of AMP-activated protein kinase pathway.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (312.12 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1212 mL	15.6060 mL	31.2120 mL
5 mM	0.6242 mL	3.1212 mL	6.2424 mL
10 mM	0.3121 mL	1.5606 mL	3.1212 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.80 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (7.80 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (7.80 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.80 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.80 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。